Keyphrases
Acute Pancreatitis
9%
Adalimumab
9%
Anti-tumor Necrosis Factor (anti-TNF)
8%
Biallelic Mismatch Repair Deficiency
9%
BMPR2
8%
Body Mass Index
14%
C-reactive Protein
8%
Celiac Disease
23%
Clinical Remission
10%
Colorectal Cancer
10%
Crohn's Disease
34%
Deficiency Diseases
9%
Disease Activity
8%
Disease Course
8%
Disease Exacerbation
8%
Endoscopy
7%
ESPGHAN
21%
Familial Adenomatous Polyposis
8%
Gastroenterology & Hepatology
8%
High Risk
8%
Hospitalization
7%
Inflammatory Bowel Disease
65%
Israel
13%
Juvenile Polyposis Syndrome
12%
Multicenter Retrospective Study
9%
Newly Diagnosed
11%
Nutritional Intervention
7%
Paediatric Gastroenterology
10%
Pediatric
21%
Pediatric Feeding Disorders
9%
Pediatric Hepatology
7%
Pediatric IBD
12%
Pediatric Inflammatory Bowel Disease
45%
Pediatric nutrition
7%
Pediatric Patients
17%
Pediatric Ulcerative Colitis
10%
Polyposis
9%
Polyposis Syndromes
13%
Porto
24%
Position Paper
10%
Posttraumatic Stress Disorder
9%
Preterm Infants
12%
Randomized Controlled Trial
25%
Remission
16%
Stress Response
9%
Ulcerative Colitis
17%
Ustekinumab
12%
Vedolizumab
10%
Vitamin D
9%
Working Diagnosis
13%
Medicine and Dentistry
Acute Pancreatitis
9%
Adolescent
27%
Adverse Event
6%
Biological Product
5%
Biological Therapy
6%
Body Mass Index
15%
Bowel Resection
6%
C Reactive Protein
5%
Coeliac Disease
22%
Colitis
10%
Colorectal Cancer
7%
Crohn's Disease
26%
Cytomegalovirus
9%
Cytomegalovirus Infection
6%
Disease
21%
Disease Activity
6%
Disease Course
8%
Disease Exacerbation
8%
DNA Mismatch Repair
12%
Elimination Diet
6%
Endoscopy
8%
Enteric Feeding
9%
Familial Adenomatous Polyposis
8%
Feeding Disorder
6%
Gastrointestinal Endoscopy
6%
Gene Disruption
6%
Helicobacter Infection
6%
Hepatology
8%
Inflammatory Bowel Disease
78%
Juvenile Polyposis Syndrome
9%
Lactose
6%
Mesalazine
6%
Observational Study
6%
Patient with Inflammatory Bowel Disease
7%
Pediatric Gastroenterology
9%
Pediatric Nutrition
7%
Pediatrics
100%
Pediatrics Patient
8%
Polyp
10%
Polyposis
22%
Prevalence
8%
Primary Health Care
5%
Randomized Controlled Trial
12%
Retrospective Study
7%
Symptom
10%
Tertiary Care
6%
Tumor Necrosis Factor
7%
Ulcerative Colitis
23%
Ustekinumab
8%
Vedolizumab
8%
